Amgen Off-label Settlement Includes Exec Oversight Of Individual Product Compliance
Amgen pled guilty to off-label promotion of Aranesp, and settled civil claims of kickbacks, false price reporting and off-label promotion of other drugs; Sanofi settles claims it provided kickbacks in the form of free Hyalgan samples.
You may also be interested in...
FTC objected to atypical Concordia deal with Par not to launch an authorized generic in return for share of profits on Par’s generic; Amgen settlement with 49 states restricts interactions with compendium.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”